Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Oct;62(4):668–670. doi: 10.1038/bjc.1990.353

Elevated CA125 levels in patients with metastatic breast carcinoma.

L Perey 1, D F Hayes 1, C Tondini 1, G van Melle 1, J Bauer 1, T Lemarchand 1, M Reymond 1, J P Mach 1, S Leyvraz 1
PMCID: PMC1971485  PMID: 2223588

Full text

PDF
668

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvarez R. D., To A., Boots L. R., Shingleton H. M., Hatch K. D., Hubbard J., Soong S. J., Potter M. E. CA125 as a serum marker for poor prognosis in ovarian malignancies. Gynecol Oncol. 1987 Mar;26(3):284–289. doi: 10.1016/0090-8258(87)90019-9. [DOI] [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  3. Buchegger F., Mettraux C., Accolla R. S., Carrel S., Mach J. P. Sandwich enzyme immunoassay using three monoclonal antibodies against different epitopes of carcinoembryonic antigen (CEA). Immunol Lett. 1982 Aug;5(2):85–91. doi: 10.1016/0165-2478(82)90038-4. [DOI] [PubMed] [Google Scholar]
  4. Canney P. A., Moore M., Wilkinson P. M., James R. D. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 1984 Dec;50(6):765–769. doi: 10.1038/bjc.1984.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fujino N., Haga Y., Sakamoto K., Egami H., Kimura M., Nishimura R., Akagi M. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen. Jpn J Clin Oncol. 1986 Dec;16(4):335–346. [PubMed] [Google Scholar]
  6. Haagensen D. E., Jr, Kister S. J., Vandevoorde J. P., Gates J. B., Smart E. K., Hansen H. J., Wells S. A., Jr Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma. Cancer. 1978 Sep;42(3 Suppl):1512–1519. doi: 10.1002/1097-0142(197809)42:3+<1512::aid-cncr2820420824>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  7. Haglund C. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. Br J Cancer. 1986 Dec;54(6):897–901. doi: 10.1038/bjc.1986.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hayes D. F., Zurawski V. R., Jr, Kufe D. W. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol. 1986 Oct;4(10):1542–1550. doi: 10.1200/JCO.1986.4.10.1542. [DOI] [PubMed] [Google Scholar]
  9. Kawahara M., Terasaki P. I., Chia D., Johnson C., Hermes M., Tokita K. Use of four monoclonal antibodies to detect tumor markers. Cancer. 1986 Nov 1;58(9):2008–2012. doi: 10.1002/1097-0142(19861101)58:9<2008::aid-cncr2820580909>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  10. Lokich J. J., Zamcheck N., Lowenstein M. W. Sequential carcinoembryonic antigen levels in the therapy of metastatic breast cancer: a predictor and monitor of response and relapse. Ann Intern Med. 1978 Dec;89(6):902–906. doi: 10.7326/0003-4819-89-6-902. [DOI] [PubMed] [Google Scholar]
  11. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  12. Myers R. E., Sutherland D. J., Meakin J. W., Kellen J. A., Malkin D. G., Malkin A. Carcinoembryonic antigen in breast cancer. Cancer. 1978 Sep;42(3 Suppl):1520–1526. doi: 10.1002/1097-0142(197809)42:3+<1520::aid-cncr2820420825>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  13. Niloff J. M., Bast R. C., Jr, Schaetzl E. M., Knapp R. C. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol. 1985 Apr 1;151(7):981–986. doi: 10.1016/0002-9378(85)90678-7. [DOI] [PubMed] [Google Scholar]
  14. Pinto M. M., Bernstein L. H., Brogan D. A., Criscuolo E. Immunoradiometric assay of CA 125 in effusions. Comparison with carcinoembryonic antigen. Cancer. 1987 Jan 15;59(2):218–222. doi: 10.1002/1097-0142(19870115)59:2<218::aid-cncr2820590207>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  15. Pons-Anicet D. M., Krebs B. P., Mira R., Namer M. Value of CA 15:3 in the follow-up of breast cancer patients. Br J Cancer. 1987 May;55(5):567–569. doi: 10.1038/bjc.1987.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ruibal A., Encabo G., Martinéz-Miralles E., Murcia C., Capdevila J. A., Salgado A., Martinéz-Vasquéz J. M. CA125 seric levels in non malignant pathologies. Bull Cancer. 1984;71(2):145–146. [PubMed] [Google Scholar]
  17. Sekine H., Hayes D. F., Ohno T., Keefe K. A., Schaetzl E., Bast R. C., Knapp R., Kufe D. W. Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol. 1985 Oct;3(10):1355–1363. doi: 10.1200/JCO.1985.3.10.1355. [DOI] [PubMed] [Google Scholar]
  18. Tondini C., Hayes D. F., Gelman R., Henderson I. C., Kufe D. W. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res. 1988 Jul 15;48(14):4107–4112. [PubMed] [Google Scholar]
  19. Tormey D. C., Waalkes T. P. Clinical correlation between CEA and breast cancer. Cancer. 1978 Sep;42(3 Suppl):1507–1511. doi: 10.1002/1097-0142(197809)42:3+<1507::aid-cncr2820420823>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  20. Tormey D. C., Waalkes T. P., Snyder J. J., Simon R. M. Biological markers in breast carcinoma. III. Clinical correlations with carcinoembryonic antigen. Cancer. 1977 Jun;39(6):2397–2404. doi: 10.1002/1097-0142(197706)39:6<2397::aid-cncr2820390614>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES